Dr Richard Williams

Publications


Journals

  • Simelyte E; Alzabin S; Boudakov I; Williams R. (Oct 2010). CD200R1 regulates the severity of arthritis but has minimal impact on the adaptive immune response. Clin Exp Immunol. 162:163-168. DOI.
  • Sacre S; Medghalchi M; Gregory B; Brennan F; Williams R. (Mar 2010). Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 62:683-693. DOI.
  • Williams R. (Feb 2009). Th17-derived cytokines: new kids on the block of inflammation. IDrugs. 12:77-79.
  • Inglis JJ; Notley CA; Essex D; Wilson AW; Feldmann M; Anand P; Williams R. (Dec 2007). Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis Rheum. 56:4015-4023. DOI.
  • Inglis JJ; Criado G; Andrews M; Feldmann M; Williams RO; Selley ML. (Sep 2007). The anti-allergic drug, N-(3',4'-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis. Rheumatology (Oxford). 46:1428-1432. DOI.
  • Williams RO. (2007). Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol Biol. 361:265-284. DOI.
  • Marinova-Mutafchieva L; Gabay C; Funa K; Williams RO. (Nov 2006). Remission of collagen-induced arthritis is associated with high levels of transforming growth factor-beta expression in the joint. Clin Exp Immunol. 146:287-293. DOI.
  • Andreakos E; Williams RO; Wales J; Foxwell BM; Feldmann M. (26 Sep 2006). Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci U S A. 103:14459-14464. DOI.
  • Wales J; Andreakos E; Foxwell B; Williams R; Buchan G; Feldmann M. (1 Dec 2005). The efficacy of NF-kappa B inducing molecules as vaccine adjuvants. IMMUNOLOGY. 116:108-108. Author weblink.
  • Williams RO; Inglis JJ; Simelyte E; Criado G; Sumariwalla PF. (Oct 2005). Analysing the effect of novel therapies on cytokine expression in experimental arthritis. Int J Exp Pathol. 86:267-278. DOI.
  • Feldmann M; Brennan FM; Foxwell BM; Taylor PC; Williams RO; Maini RN. (2005). Anti-TNF therapy: where have we got to in 2005?. J Autoimmun. 25 Suppl:26-28. DOI.
  • Williams RO. (2005). Models of rheumatoid arthritis. Ernst Schering Res Found Workshop. 89-117.
  • Nedvetzki S; Gonen E; Assayag N; Reich R; Williams RO; Thurmond RL; Huang JF; Neudecker BA; et alWang FS; Turley EA; Naor D. (28 Dec 2004). RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A. 101:18081-18086. DOI.
  • Taylor PC; Williams RO; Feldmann M. (Dec 2004). Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol. 15:557-563. DOI.
  • Feldmann M; Brennan FM; Williams RO; Woody JN; Maini RN. (Feb 2004). The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 18:59-80. DOI.
  • Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN. (2004). Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?. Novartis Found Symp. 256:53-69.
  • Williams RO. (2004). Collagen-induced arthritis as a model for rheumatoid arthritis. Methods Mol Med. 98:207-216. DOI.
  • Ozegbe P; Foey AD; Ahmed S; Williams RO. (Jan 2004). Impact of cAMP on the T-cell response to type II collagen. Immunology. 111:35-40.
  • Mauri C; Feldmann M; Williams RO. (Mar 2003). Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response. Arthritis Rheum. 48:839-845. DOI.
  • Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R. (2003). Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther. 5:R317-R328. DOI.
  • Williams RO. (1 Jun 2002). Cutting edge: A-kinase anchor proteins are involved in maintaining resting T cells in an inactive state. J Immunol. 168:5392-5396.
  • Marinova-Mutafchieva L; Williams RO; Funa K; Maini RN; Zvaifler NJ. (Feb 2002). Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum. 46:507-513.
  • Williams RO. (Jan 2002). Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum. 46:271-273. DOI.
  • Taylor PC; Williams RO; Maini RN. (Oct 2001). Immunotherapy for rheumatoid arthritis. Curr Opin Immunol. 13:611-616.
  • Malfait AM; Williams RO; Malik AS; Maini RN; Feldmann M. (May 2001). Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis Rheum. 44:1215-1224. DOI.
  • Gabay C; Marinova-Mutafchieva L; Williams RO; Gigley JP; Butler DM; Feldmann M; Arend WP. (Feb 2001). Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis. Arthritis Rheum. 44:451-462. DOI.

Chapters in books

  • Feldmann M; Brennan F; Williams RO; Maini RN. Definition of TNFalpha as a therapeutic target for rheumatoid arthritis. In TNFalpha inhibition in the treatment of rheumatoid arthritis. 1-22. Moreland E (ed). Martin Dunitz, London (2003).

Patents

  • Treatment of Rheumatoid Arthritis with Anti-CD4 Antibodies in Conjuction anti-TNF Antibodies. Patent number: US 5,741,488. European Patent No 0 663 836. Feldmann M; Maini RN. Published: 21 Apr 1998.
  • TNFalpha antagonists and cyclosporin in therapy of rheumatoid arthritis. Patent number: US 6,770,279. Feldmann M; Maini RN. Published: 3 Aug 2004.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook